What the alcohol doctor ordered from the neuroscientist: Theragnostic biomarkers for personalized treatments

Progress in Brain Research

Volumn 224, Issue , 2016, Pages 401-418

  Heilig, Markus ^a   Leggio, Lorenzo ^b,c  

^a LINKÖPING UNIVERSITY   (Sweden)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Alcoholism; Biomarker; Dopamine; Glutamate; Pharmacogenetic; Theragnostic

Indexed keywords

BIOLOGICAL MARKER; DOPAMINE; GLUTAMIC ACID;

ALCOHOLISM; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; NEUROSCIENCE; NUCLEAR MAGNETIC RESONANCE; PERSONALIZED MEDICINE; PHARMACOGENETICS; POSITRON EMISSION TOMOGRAPHY; THERAGNOSTIC; BRAIN; GENETICS; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REWARD;

ALCOHOLISM; BIOMARKERS; BRAIN; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOGENETICS; PRECISION MEDICINE; REWARD;

EID: 84949991497     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/bs.pbr.2015.07.023     Document Type: Chapter

References (83)

1. Altshuler H.L., Phillips P.E., Feinhandler D.A. Alteration of ethanol self-administration by naltrexone. Life Sci. 1980, 26:679-688.
2. American Psychiatric Association Diagnostic Criteria from DSM-IV-TR 2000, American Psychiatric Association, Washington, DC.
3. Babor T.F., Dolinsky Z.S., Meyer R.E., Hesselbrock M., Hofmann M., Tennen H. Types of alcoholics: concurrent and predictive validity of some common classification schemes. Br. J. Addict. 1992, 87:1415-1431.
4. Bak L.K., Schousboe A., Waagepetersen H.S. The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J. Neurochem. 2006, 98:641-653.
5. Barr C.S., Schwandt M., Lindell S.G., Chen S.A., Goldman D., Suomi S.J., Higley J.D., Heilig M. Association of a functional polymorphism in the mu-opioid receptor gene with alcohol response and consumption in male rhesus macaques. Arch. Gen. Psychiatry 2007, 64:369-376.
6. Bergen S.E., Gardner C.O., Kendler K.S. Age-related changes in heritability of behavioral phenotypes over adolescence and young adulthood: a meta-analysis. Twin Res. Hum. Genet. 2007, 10:423-433.
7. Bilbao A., Robinson J.E., Heilig M., Malanga C.J., Spanagel R., Sommer W.H., Thorsell A. A pharmacogenetic determinant of mu-opioid receptor antagonist effects on alcohol reward and consumption: evidence from humanized mice. Biol. Psychiatry 2015, 77:850-858.
8. Boileau I., Assaad J.M., Pihl R.O., Benkelfat C., Leyton M., Diksic M., Tremblay R.E., Dagher A. Alcohol promotes dopamine release in the human nucleus accumbens. Synapse 2003, 49:226-231.
9. Bond C., LaForge K.S., Tian M., Melia D., Zhang S., Borg L., Gong J., Schluger J., Strong J.A., Leal S.M., Tischfield J.A., Kreek M.J., Yu L. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl. Acad. Sci. USA 1998, 95:9608-9613.
10. Brand I., Fliegel S., Spanagel R., Noori H.R. Global ethanol-induced enhancements of monoaminergic neurotransmission: a meta-analysis study. Alcohol. Clin. Exp. Res. 2013, 37:2048-2057.
11. Brandon T.H., Vidrine J.I., Litvin E.B. Relapse and relapse prevention. Annu. Rev. Clin. Psychol. 2007, 3:257-284.
12. Brown J., Babor T.F., Litt M.D., Kranzler H.R. The type A/type B distinction. Subtyping alcoholics according to indicators of vulnerability and severity. Ann. N. Y. Acad. Sci. 1994, 708:23-33.
13. Caspi A., Hariri A.R., Holmes A., Uher R., Moffitt T.E. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am. J. Psychiatry 2010, 167:509-527.
14. Chamorro A.J., Marcos M., Miron-Canelo J.A., Pastor I., Gonzalez-Sarmiento R., Laso F.J. Association of mu-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. Addict. Biol. 2012, 17:505-512.
15. Chin C.L., Upadhyay J., Marek G.J., Baker S.J., Zhang M., Mezler M., Fox G.B., Day M. Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals. J. Pharmacol. Exp. Ther. 2011, 336:709-715.
16. Cippitelli A., Karlsson C., Shaw J.L., Thorsell A., Gehlert D.R., Heilig M. Suppression of alcohol self-administration and reinstatement of alcohol seeking by melanin-concentrating hormone receptor 1 (MCH1-R) antagonism in Wistar rats. Psychopharmacology (Berl.) 2010, 211:367-375.
17. Cloninger C.R. Neurogenetic adaptive mechanisms in alcoholism. Science 1987, 236:410-416.
18. Dewey S.L., Smith G.S., Logan J., Brodie J.D., Fowler J.S., Wolf A.P. Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 1993, 13:350-356.
19. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA 1988, 85:5274-5278.
20. Edwards G., Gross M.M. Alcohol dependence: provisional description of a clinical syndrome. Br. Med. J. 1976, 1:1058-1061.
21. Endres C.J., Kolachana B.S., Saunders R.C., Su T., Weinberger D., Breier A., Eckelman W.C., Carson R.E. Kinetic modeling of [11C]raclopride: combined PET-microdialysis studies. J. Cereb. Blood Flow Metab. 1997, 17:932-942.
22. Fliegel S., Brand I., Spanagel R., Noori H.R. Ethanol-induced alterations of amino acids measured by in vivo microdialysis in rats: a meta-analysis. In Silico Pharmacol. 2013, 1:7.
23. Garbutt J.C., Greenblatt A.M., West S.L., Morgan L.C., Kampov-Polevoy A., Jordan H.S., Bobashev G.V. Clinical and biological moderators of response to Naltrexone in alcohol dependence: a systematic review of the evidence. Addiction 2014, 109:1274-1284.
24. Gass J.T., Trantham-Davidson H., Kassab A.S., Glen W.B., Olive M.F., Chandler L.J. Enhancement of extinction learning attenuates ethanol-seeking behavior and alters plasticity in the prefrontal cortex. J. Neurosci. 2014, 34:7562-7574.
25. Gilman J.M., Ramchandani V.A., Davis M.B., Bjork J.M., Hommer D.W. Why we like to drink: a functional magnetic resonance imaging study of the rewarding and anxiolytic effects of alcohol. J. Neurosci. 2008, 28:4583-4591.
26. Gilman J.M., Ramchandani V.A., Crouss T., Hommer D.W. Subjective and neural responses to intravenous alcohol in young adults with light and heavy drinking patterns. Neuropsychopharmacology 2012, 37:467-477.
27. Gladstone D.J., Black S.E., Hakim A.M., Heart, Stroke Foundation of Ontario Centre of Excellence in Stroke Recovery Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002, 33:2123-2136.
28. Glockner-Rist A., Lemenager T., Mann K., Group PSR Reward and relief craving tendencies in patients with alcohol use disorders: results from the PREDICT study. Addict. Behav. 2013, 38:1532-1540.
29. Goldman D., Oroszi G., Ducci F. The genetics of addictions: uncovering the genes. Nat. Rev. Genet. 2005, 6:521-532.
30. Gonzales R.A., Weiss F. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J. Neurosci. 1998, 18:10663-10671.
31. Gottesman I.I., Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 2003, 160:636-645.
32. Gowin J.L., Harle K.M., Stewart J.L., Wittmann M., Tapert S.F., Paulus M.P. Attenuated insular processing during risk predicts relapse in early abstinent methamphetamine-dependent individuals. Neuropsychopharmacology 2014, 39:1379-1387.
33. Grant B.F., Stinson F.S., Dawson D.A., Chou S.P., Dufour M.C., Compton W., Pickering R.P., Kaplan K. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch. Gen. Psychiatry 2004, 61:807-816.
34. Heilig M., Egli M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol. Ther. 2006, 111:855-876.
35. Heilig M., Egli M., Crabbe J.C., Becker H.C. Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked?. Addict. Biol. 2010, 15:169-184.
36. Heilig M., Goldman D., Berrettini W., O'Brien C.P. Pharmacogenetic approaches to the treatment of alcohol addiction. Nat. Rev. Neurosci. 2011, 12:670-684.
37. Hermann D., Weber-Fahr W., Sartorius A., Hoerst M., Frischknecht U., Tunc-Skarka N., Perreau-Lenz S., Hansson A.C., Krumm B., Kiefer F., Spanagel R., Mann K., Ende G., Sommer W.H. Translational magnetic resonance spectroscopy reveals excessive central glutamate levels during alcohol withdrawal in humans and rats. Biol. Psychiatry 2012, 71:1015-1021.
38. Hester R.K., Miller W.R. Handbook of Alcoholism Treatment Approaches: Effective Alternatives 1995, Allyn and Bacon, Boston.
39. Holmes A., Spanagel R., Krystal J.H. Glutamatergic targets for new alcohol medications. Psychopharmacology (Berl.) 2013, 229:539-554.
40. Hunt W.A., Barnett L.W., Branch L.G. Relapse rates in addiction programs. J. Clin. Psychol. 1971, 27:455-456.
41. Hurd R., Sailasuta N., Srinivasan R., Vigneron D.B., Pelletier D., Nelson S.J. Measurement of brain glutamate using TE-averaged PRESS at 3 T. Magn. Reson. Med. 2004, 51:435-440.
42. Hyman S.E. Revolution stalled. Sci. Transl. Med. 2012, 4:155cm111.
43. Jerlhag E., Egecioglu E., Dickson S.L., Andersson M., Svensson L., Engel J.A. Ghrelin stimulates locomotor activity and accumbal dopamine-overflow via central cholinergic systems in mice: implications for its involvement in brain reward. Addict. Biol. 2006, 11:45-54.
44. Jerlhag E., Egecioglu E., Landgren S., Salome N., Heilig M., Moechars D., Datta R., Perrissoud D., Dickson S.L., Engel J.A. Requirement of central ghrelin signaling for alcohol reward. Proc. Natl. Acad. Sci. USA 2009, 106:11318-11323.
45. Johnson B.A., Seneviratne C., Wang X.Q., Ait-Daoud N., Li M.D. Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron. Am. J. Psychiatry 2013, 170:1020-1031.
46. Jonas D.E., Amick H.R., Feltner C., Bobashev G., Thomas K., Wines R., Kim M.M., Shanahan E., Gass C.E., Rowe C.J., Garbutt J.C. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 2014, 311:1889-1900.
47. Khin N.A., Chen Y.F., Yang Y., Yang P., Laughren T.P. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J. Clin. Psychiatry 2011, 72:464-472.
48. Knutson B., Gibbs S.E. Linking nucleus accumbens dopamine and blood oxygenation. Psychopharmacology (Berl.) 2007, 191:813-822.
49. Koob G.F., Le Moal M. Addiction and the brain antireward system. Annu. Rev. Psychol. 2008, 59:29-53.
50. Kranzler H.R., Covault J., Feinn R., Armeli S., Tennen H., Arias A.J., Gelernter J., Pond T., Oncken C., Kampman K.M. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am. J. Psychiatry 2014, 171:445-452.
51. Landgren S., Simms J.A., Hyytia P., Engel J.A., Bartlett S.E., Jerlhag E. Ghrelin receptor (GHS-R1A) antagonism suppresses both operant alcohol self-administration and high alcohol consumption in rats. Addict. Biol. 2012, 17:86-94.
52. Litten R.Z., Egli M., Heilig M., Cui C., Fertig J.B., Ryan M.L., Falk D.E., Moss H., Huebner R., Noronha A. Medications development to treat alcohol dependence: a vision for the next decade. Addict. Biol. 2012, 17:513-527.
53. Mark T.L., Kranzler H.R., Song X. Understanding US addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend. 2003, 71:219-228.
54. Mark T.L., Kassed C.A., Vandivort-Warren R., Levit K.R., Kranzler H.R. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009, 99:345-349.
55. Martinez D., Gil R., Slifstein M., Hwang D.R., Huang Y., Perez A., Kegeles L., Talbot P., Evans S., Krystal J., Laruelle M., Abi-Dargham A. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol. Psychiatry 2005, 58:779-786.
56. Meinhardt M.W., Sommer W.H. Postdependent state in rats as a model for medication development in alcoholism. Addict. Biol. 2015, 20:1-21.
57. Meinhardt M.W., Hansson A.C., Perreau-Lenz S., Bauder-Wenz C., Stahlin O., Heilig M., Harper C., Drescher K.U., Spanagel R., Sommer W.H. Rescue of infralimbic mGluR2 deficit restores control over drug-seeking behavior in alcohol dependence. J. Neurosci. 2013, 33:2794-2806.
58. Miller G. Is pharma running out of brainy ideas?. Science 2010, 329:502-504.
59. Munafo M.R., Brown S.M., Hariri A.R. Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis. Biol. Psychiatry 2008, 63:852-857.
60. Nutt D.J., King L.A., Phillips L.D., Independent Scientific Committee on D Drug harms in the UK: a multicriteria decision analysis. Lancet 2010, 376:1558-1565.
61. O'Malley S.S., Jaffe A.J., Chang G., Schottenfeld R.S., Meyer R.E., Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch. Gen. Psychiatry 1992, 49:881-887.
62. Oslin D.W., Berrettini W., Kranzler H.R., Pettinati H., Gelernter J., Volpicelli J.R., O'Brien C.P. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003, 28:1546-1552.
63. Oslin D.W., Leong S.H., Lynch K.G., Berrettini W., O'Brien C.P., Gordon A.J., Rukstalis M. Naltrexone vs placebo for the treatment of alcohol dependence: a randomized clinical trial. JAMA Psychiatry 2015, 72:430-437.
64. Ozdemir V., Williams-Jones B., Glatt S.J., Tsuang M.T., Lohr J.B., Reist C. Shifting emphasis from pharmacogenomics to theragnostics. Nat. Biotechnol. 2006, 24:942-946.
65. Ramchandani V.A., Bolane J., Li T.K., O'Connor S. A physiologically-based pharmacokinetic (PBPK) model for alcohol facilitates rapid BrAC clamping. Alcohol. Clin. Exp. Res. 1999, 23:617-623.
66. Ramchandani V.A., Umhau J., Pavon F.J., Ruiz-Velasco V., Margas W., Sun H., Damadzic R., Eskay R., Schoor M., Thorsell A., Schwandt M.L., Sommer W.H., George D.T., Parsons L.H., Herscovitch P., Hommer D., Heilig M. A genetic determinant of the striatal dopamine response to alcohol in men. Mol. Psychiatry 2011, 16:809-817.
67. Rossetti Z.L., Carboni S. Ethanol withdrawal is associated with increased extracellular glutamate in the rat striatum. Eur. J. Pharmacol. 1995, 283:177-183.
68. Shibata M.C., Flather M.D., Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur. J. Heart Fail. 2001, 3:351-357.
69. Spagnolo P.A., Ramchandani V.A., Schwandt M.L., Zhang L., Blaine S.K., Usala J.M., Diamond K.A., Phillips M.J., George D.T., Momenan R., Heilig M. Effects of naltrexone on neural and subjective response to alcohol in treatment-seeking alcohol-dependent patients. Alcohol. Clin. Exp. Res. 2014, 38:3024-3032.
70. Spanagel R. Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol. Rev. 2009, 89:649-705.
71. Spanagel R. Are metabotropic glutamate receptors promising targets for the treatment of alcoholism?. Biol. Psychiatry 2010, 67:798-799.
72. Spanagel R., Kiefer F. Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol. Sci. 2008, 29:109-115.
73. Spanagel R., Pendyala G., Abarca C., Zghoul T., Sanchis-Segura C., Magnone M.C., Lascorz J., Depner M., Holzberg D., Soyka M., Schreiber S., Matsuda F., Lathrop M., Schumann G., Albrecht U. The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nat. Med. 2005, 11:35-42.
74. Srinivasan R., Cunningham C., Chen A., Vigneron D., Hurd R., Nelson S., Pelletier D. TE-averaged two-dimensional proton spectroscopic imaging of glutamate at 3 T. NeuroImage 2006, 30:1171-1178.
75. Tanda G., Di Chiara G. A dopamine-mu1 opioid link in the rat ventral tegmentum shared by palatable food (Fonzies) and non-psychostimulant drugs of abuse. Eur. J. Neurosci. 1998, 10:1179-1187.
76. Umhau J.C., Momenan R., Schwandt M.L., Singley E., Lifshitz M., Doty L., Adams L.J., Vengeliene V., Spanagel R., Zhang Y., Shen J., George D.T., Hommer D., Heilig M. Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch. Gen. Psychiatry 2010, 67:1069-1077.
77. Urban N.B., Kegeles L.S., Slifstein M., Xu X., Martinez D., Sakr E., Castillo F., Moadel T., O'Malley S.S., Krystal J.H., Abi-Dargham A. Sex differences in striatal dopamine release in young adults after oral alcohol challenge: a positron emission tomography imaging study with [(11)C]raclopride. Biol. Psychiatry 2010, 68:689-696.
78. Volpicelli J.R., Alterman A.I., Hayashida M., O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry 1992, 49:876-880.
79. Weiss F., Lorang M.T., Bloom F.E., Koob G.F. Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. J. Pharmacol. Exp. Ther. 1993, 267:250-258.
80. Whiteford H.A., Degenhardt L., Rehm J., Baxter A.J., Ferrari A.J., Erskine H.E., Charlson F.J., Norman R.E., Flaxman A.D., Johns N., Burstein R., Murray C.J., Vos T. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013, 382:1575-1586.
81. Wise R.A., Bozarth M.A. A psychomotor stimulant theory of addiction. Psychol. Rev. 1987, 94:469-492.
82. Wu C.C., Samanez-Larkin G.R., Katovich K., Knutson B. Affective traits link to reliable neural markers of incentive anticipation. NeuroImage 2014, 84:279-289.
83. Zhou Z., Karlsson C., Liang T., Xiong W., Kimura M., Tapocik J.D., Yuan Q., Barbier E., Feng A., Flanigan M., Augier E., Enoch M.A., Hodgkinson C.A., Shen P.H., Lovinger D.M., Edenberg H.J., Heilig M., Goldman D. Loss of metabotropic glutamate receptor 2 escalates alcohol consumption. Proc. Natl. Acad. Sci. USA 2013, 110:16963-16968.